Compare BioNTech SE - ADR (BNTX) vs ProShares Ultra Bloomberg Natural Gas ETF (BOIL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs ProShares Ultra Bloomberg Natural Gas ETF — how do they compare? BioNTech SE - ADR trades at $92.98 (market cap $23.31B), while ProShares Ultra Bloomberg Natural Gas ETF trades at $20.86. The key difference: BioNTech SE - ADR is trading nearer its 52-week high, ProShares Ultra Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| BNTX | BOIL | |
|---|---|---|
Market Cap | $23.31B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $119.34 | $87.24 |
52-Week Low | $83.89 | $18.74 |
Enterprise Value | $6.60B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
BOIL trades at $21.085, up 1.81% in the last 24 hours, with a bearish technical signal from moving averages and neutral oscillators. Recent news highlights U.S. natural gas futures stability amid weather-driven demand shifts. The company, Beyond Oil Ltd., focuses on food-tech innovations to reduce health risks in fried foods, with recent corporate actions including a 1:2 stock split effective May 28, 2026.
The outlook for BOIL is cautious due to bearish technical trends and reliance on natural gas market volatility. Investment opportunities hinge on energy sector demand and company-specific growth in food-tech, while risks include commodity price swings and execution challenges in scaling innovations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About ProShares Ultra Bloomberg Natural Gas ETF
BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.
Read more on BOIL →
